Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy

Recruiting 240 enrolled St. Petersburg State Pavlov Medical University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The open-label prospective non-randomised controlled aims to assess the efficacy of the combination of immunosupression (IST) and tonsillectomy (TE) in Caucasian patients at high risk of the IgA-nephropathy.

Timeline

Start: 2013-03-10
Primary completion: 2026-03-10
Completion: 2027-12-10

Publications

Background Barbour SJ, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Er L, Espino-Hernandez G, Kim SJ, Reich HN, Feehally J, Cattran DC; International IgA Nephropathy Network. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Methylprednisolone	Other / unclassified	500 mg	Intravenous
Background	Methylprednisolone	Other / unclassified	1000 mg	Intravenous
Background	Prednisolone	Other / unclassified	5 mg	Oral
Background	mycophenolic acid	Small molecule	—	—

Tonsillectomy and Immunosuppression in Caucasian Patients With High-risk IgA-nephropathy

Summary

Timeline

Publications

Drugs

Indications